Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-56021927 and Abiraterone Acetate in Metastatic Castration-Resistant Prostate Cancer
NCT02123758Phase 1Active, not recruiting
- Sponsor
- Aragon Pharmaceuticals
- Start
- Jul 2014
- Primary completion
- Jun 2016
- Modality
- Orthosteric Ligands
- Countries
- 4
01
Overview
Phase 1, open-label trial of apalutamide in metastatic castration-resistant prostate cancer (mCRPC) (2 cohorts), sponsored by Aragon Pharmaceuticals. Primary endpoints: Area Under the Plasma Concentration-time Curve From Time Zero to Time 24 Hours of abiraterone, Maximum plasma concentration of abiraterone, prednisone and its metabolite prednisolone at Day 36 and 1 more. Started Jul 2014; status: active, not recruiting.
02
Drugs
apalutamide
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT02123758.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02123758.